Adamis Pharmaceuticals Corporation (ADMP) financial statements (2022 and earlier)
Company profile
| Business Address |
11682 EL CAMINO REAL SAN DIEGO, CA 92130 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 9 | 19 | 17 | 5 | 4 | 5 | |||
| Cash and cash equivalents | 9 | 19 | 17 | 4 | 4 | 5 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 1 | ||||||||
| Receivables | (0) | (0) | |||||||
| Inventory, net of allowances, customer advances and progress billings | 2 | 3 | 2 | 1 | ✕ | ||||
| Inventory | 2 | 3 | 2 | 1 | |||||
| Prepaid expense | 1 | 1 | 0 | 0 | 0 | 0 | |||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed current assets | 2 | 3 | 2 | 1 | |||||
| Total current assets: | 14 | 26 | 21 | 7 | 4 | 5 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 2 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 12 | 10 | 7 | 5 | 0 | 0 | |||
| Intangible assets, net (including goodwill) | 19 | 21 | 23 | 26 | 8 | 10 | |||
| Goodwill | 8 | 8 | 8 | 8 | |||||
| Intangible assets, net (excluding goodwill) | 11 | 13 | 16 | 18 | 8 | 10 | |||
| Deposits noncurrent assets | 0 | 0 | 0 | 0 | 0 | ||||
| Other noncurrent assets | 2 | 2 | |||||||
| Total noncurrent assets: | 34 | 33 | 30 | 31 | 8 | 10 | |||
| TOTAL ASSETS: | 48 | 58 | 51 | 38 | 12 | 15 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 7 | 8 | 6 | 4 | 1 | 1 | |||
| Accounts payable | 4 | 4 | 3 | 2 | 0 | 1 | |||
| Accrued liabilities | 2 | 2 | 2 | 2 | 0 | 0 | |||
| Employee-related liabilities | 1 | 1 | 0 | 0 | |||||
| Deferred revenue | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Debt | 3 | 3 | 2 | 4 | 0 | ||||
| Deferred compensation liability | 1 | ||||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | 0 | 0 | ||||
| Other liabilities | 1 | ||||||||
| Other undisclosed current liabilities | 1 | 0 | 0 | ||||||
| Total current liabilities: | 10 | 12 | 9 | 9 | 3 | 3 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1 | 3 | 3 | ||||||
| Long-term debt, excluding current maturities | 3 | 3 | |||||||
| Finance lease, liability | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, liability | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 1 | |||||
| Deferred tax liabilities, net | ✕ | ✕ | 0 | 0 | 1 | ||||
| Deferred income tax liabilities | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Total noncurrent liabilities: | 2 | 0 | 3 | 4 | |||||
| Total liabilities: | 12 | 12 | 12 | 13 | 3 | 3 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 36 | 47 | 40 | 25 | 9 | 12 | |||
| Preferred stock | 0 | 0 | |||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Treasury stock, value | (0) | (0) | (0) | (0) | (0) | (0) | |||
| Additional paid in capital | 218 | 200 | 154 | 114 | 78 | 58 | |||
| Accumulated deficit | (182) | (153) | (114) | (88) | (69) | (46) | |||
| Total stockholders' equity: | 36 | 47 | 40 | 25 | 9 | 12 | |||
| TOTAL LIABILITIES AND EQUITY: | 48 | 58 | 51 | 38 | 12 | 15 | |||
Income statement (P&L) ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 22 | 15 | 13 | 6 | ||||
| Revenue, net | ✕ | ✕ | ✕ | 13 | 6 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (15) | (10) | (7) | (5) | ||||
| Gross profit: | 7 | 5 | 6 | 2 | ||||
| Operating expenses | (36) | (45) | (30) | (27) | (14) | (5) | ||
| Other undisclosed operating income | 1 | |||||||
| Operating loss: | (29) | (39) | (25) | (25) | (14) | (4) | ||
| Nonoperating income (expense) | 0 | 0 | (1) | 1 | 0 | (4) | ||
| Investment income, nonoperating | 0 | 0 | 0 | 0 | 1 | |||
| Interest and debt expense | (0) | (0) | (0) | (0) | (9) | |||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (29) | (40) | (26) | (24) | (14) | (17) | ||
| Other undisclosed income from continuing operations before income taxes | 0 | 0 | 0 | |||||
| Loss from continuing operations before income taxes: | (29) | (39) | (26) | (24) | (14) | (17) | ||
| Income tax expense (benefit) | (0) | 0 | 0 | 5 | ||||
| Other undisclosed income from continuing operations | 9 | |||||||
| Net loss attributable to parent: | (29) | (39) | (26) | (19) | (14) | (8) | ||
| Preferred stock dividends and other adjustments | (1) | |||||||
| Other undisclosed net income available to common stockholders, basic | 78 | |||||||
| Net income (loss) available to common stockholders, basic: | (29) | 39 | (26) | (21) | (14) | (8) | ||
| Dilutive securities, effect on basic earnings per share | (0) | |||||||
| Other undisclosed net loss available to common stockholders, diluted | (1) | |||||||
| Net income (loss) available to common stockholders, diluted: | (29) | 39 | (26) | (21) | (14) | (9) | ||
Comprehensive Income ($ in millions)
| 9/30/2020 TTM | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 3/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (29) | (39) | (26) | (19) | (14) | (8) | ||
| Comprehensive loss, net of tax, attributable to parent: | (29) | (39) | (26) | (19) | (14) | (8) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.